RT @journal_CHEST: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @journal_CHEST: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs…
RT @journal_CHEST: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs…
RT @journal_CHEST: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs…
RT @journal_CHEST: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs…
RT @journal_CHEST: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs…
Patients with IPF who used nintedanib had a slower 12-month FVC decline than pirfenidone in a post hoc analysis of a clinical trial
これらはやはり副作用がどうの、という使い分けになるのかな
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs those treated with nintedanib? Read the full research in the May issue: https://t.co/ASOYnAtChm #JournalCHEST #MedEd https://t.co/9eOkH
Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs those treated with nintedanib? Read the full research in the May issue: https://t.co/GYhdsUy3ct #JournalCHEST #MedEd https://t.co/Yo32l
RT @tipssovetorax: Comparación de pirfenidona y nintedanib. Estudio post hoc de CleanUP-IPF https://t.co/hQunxZv8YF
RT @tipssovetorax: Comparación de pirfenidona y nintedanib. Estudio post hoc de CleanUP-IPF https://t.co/hQunxZv8YF
RT @tipssovetorax: Comparación de pirfenidona y nintedanib. Estudio post hoc de CleanUP-IPF https://t.co/hQunxZv8YF
RT @tipssovetorax: Comparación de pirfenidona y nintedanib. Estudio post hoc de CleanUP-IPF https://t.co/hQunxZv8YF
RT @tipssovetorax: Comparación de pirfenidona y nintedanib. Estudio post hoc de CleanUP-IPF https://t.co/hQunxZv8YF
Comparación de pirfenidona y nintedanib. Estudio post hoc de CleanUP-IPF https://t.co/hQunxZv8YF
RT @37phoenix: 特発性肺線維症の患者においてニンテダニブの使用はピルフェニドンと比較して12ヶ月後のFVCの低下が緩やかだった。CleanUP-IPF試験の事後解析. Chest. 2024;165:1163. PMID: 38030064. https://t.…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @37phoenix: 特発性肺線維症の患者においてニンテダニブの使用はピルフェニドンと比較して12ヶ月後のFVCの低下が緩やかだった。CleanUP-IPF試験の事後解析. Chest. 2024;165:1163. PMID: 38030064. https://t.…
RT @37phoenix: 特発性肺線維症の患者においてニンテダニブの使用はピルフェニドンと比較して12ヶ月後のFVCの低下が緩やかだった。CleanUP-IPF試験の事後解析. Chest. 2024;165:1163. PMID: 38030064. https://t.…
特発性肺線維症の患者においてニンテダニブの使用はピルフェニドンと比較して12ヶ月後のFVCの低下が緩やかだった。CleanUP-IPF試験の事後解析. Chest. 2024;165:1163. PMID: 38030064. https://t.co/mhmB9ec9xn
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @ILDinfo: This is a super important paper (!) comparing the two approved antifibrotics nintedanib and pirfenidone for idiopathic pulmona…
RT @ILDinfo: This is a super important paper (!) comparing the two approved antifibrotics nintedanib and pirfenidone for idiopathic pulmona…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @ILDinfo: This is a super important paper (!) comparing the two approved antifibrotics nintedanib and pirfenidone for idiopathic pulmona…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @ILDinfo: This is a super important paper (!) comparing the two approved antifibrotics nintedanib and pirfenidone for idiopathic pulmona…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study - ScienceDirect https://t.co/DePvyTpKQV
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
This is a super important paper (!) comparing the two approved antifibrotics nintedanib and pirfenidone for idiopathic pulmonary fibrosis (IPF). 🫁 READ MORE: Choosing either pirfenidone or nintedanib for treating IPF is based on several factors: patient pr
RT @accpchest: Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs tho…
Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs those treated with nintedanib? Read the full research in the latest issue: https://t.co/jkvE7G2Xe4 #JournalCHEST #MedEd https://t.co/Ph
Are there differences in 12-month FVC decline in patients with idiopathic pulmonary fibrosis treated with pirfenidone vs those treated with nintedanib? Read the full research in the latest @journal_CHEST issue: https://t.co/ytBZFV1AT5 #MedTwitter #MedEd ht
RT @NeumologiaPeru: 🔥🔥Comparison of Pirfenidone and Nintedanib: Post-Hoc Analysis of the CleanUP-IPF Study ✅Patients with IPF who used nin…
RT @NeumologiaPeru: 🔥🔥Comparison of Pirfenidone and Nintedanib: Post-Hoc Analysis of the CleanUP-IPF Study ✅Patients with IPF who used nin…
RT @NeumologiaPeru: 🔥🔥Comparison of Pirfenidone and Nintedanib: Post-Hoc Analysis of the CleanUP-IPF Study ✅Patients with IPF who used nin…
🔥🔥Comparison of Pirfenidone and Nintedanib: Post-Hoc Analysis of the CleanUP-IPF Study ✅Patients with IPF who used nintedanib had a slower 12-month FVC decline than pirfenidone @KerriBerriKerri @DrPujaMehta1 @PilarRiveraOrt1 @leticiakawano https://t.co
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @leticiakawano: See the thread 🧵 below: 💥
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
See the thread 🧵 below: 💥
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
RT @jskim8223: Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX
Our paper is out in @accpchest comparing antifibrotics in IPF👇 https://t.co/QB62Det6VN https://t.co/CPBVkSb8QX